Results 51 to 60 of about 56,599 (248)

Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study

Journal of Dermatological Treatment
Background The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis.Objective To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab.Methods Data were extracted from
Axel Svedbom, Christina Wennerström, Fredrik Hjelm, Anna Tjärnlund, Mona Ståhle   +4 more
doaj   +1 more source

Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain‐of‐function pathogenic variants in the SMAD4 gene, a key player in TGF‐β signaling and a regulator of extracellular matrix homeostasis.
Alessandro De Falco, Alfonso Manuel D'Alessio, Nicola Brunetti‐Pierri   +2 more
wiley   +1 more source

SUCCESSFUL USE OF ETANERCEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITH AN OVERVIEW OF THE PREDICTORS OF A GOOD RESPONSE TO ONGOING THERAPY

Вопросы современной педиатрии, 2017
The  article  presents  a case  of  polyarticular  juvenile  idiopathic  arthritis  resistant  to  methotrexate  therapy  and  nonsteroidal  antiinflammatory drugs.  The child was prescribed  a tumor necrosis  factor   inhibitor etanercept  at a dose  of
Anna V. Karaseva, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya   +2 more
doaj   +1 more source

Stem cell–based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection

Animal Models and Experimental Medicine, EarlyView.
Directed differentiation of pluripotent stem cells into functional pancreatic β cells have emerged as a promising strategy for the radical treatment of type 1 diabetes, with preclinical and early clinical evidence demonstrating reversal of hyperglycemia and insulin independence.
Zifan Li, Yu Kang, Yuyu Niu
wiley   +1 more source

A case of figurate urticaria by etanercept [PDF]

, 2016
Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, involved in the development of the immune system, in host defense and immune surveillance.
Mascolo, Annamaria, Romano, Francesca Valentina, Sessa, Maurizio, Sullo, Maria Giuseppa, Schiavo, Ada Lo, ROSSI, Francesco, Puca, Rosa, Cimmaruta, Daniela, CAPUANO, Annalisa   +8 more
core   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

High Levels of Tumor Necrosis Factor-Alpha Reduce Placental Aquaporin 3 Expression and Impair in vitro Trophoblastic Cell Migration

Frontiers in Physiology, 2021
Placentas from preeclamptic women display augmented tumor necrosis factor-alpha (TNF-α) levels with reduced expression of aquaporin 3 (AQP3). However, whether TNF-α modulates AQP3 expression remains to be elucidated.
Rinaldo Rodrigues dos Passos Junior, Raiany Alves de Freitas, Julieta Reppetti, Yollyseth Medina, Vanessa Dela Justina, Camila Werle Bach, Gisele Facholi Bomfim, Victor Vitorino Lima, Alicia E. Damiano, Alicia E. Damiano, Fernanda R. Giachini, Fernanda R. Giachini   +11 more
doaj   +1 more source

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy

Experimental Hematology & Oncology, 2021
Cytokine release syndrome (CRS) is the most common toxicity induced by chimeric antigen receptor (CAR) T cell therapy. At present, anti-IL-6 agents including tocilizumab and siltuximab have been applied in the treatment of CRS.
Lina Zhang, Shuai Wang, Ji Xu, Run Zhang, Han Zhu, Yujie Wu, Liying Zhu, Jianyong Li, Lijuan Chen   +8 more
doaj   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source